SV203

SV203 is a preclinical-stage bispecific nanobody candidate developed by Sysvax for the treatment of multiple tumor types. It is engineered to target two distinct immune checkpoint molecules, aiming to overcome resistance mechanisms associated with single-agent checkpoint inhibition and to provide a more potent anti-tumor immune response. As a nanobody-based therapeutic, SV203 leverages the small size and high stability of single-domain antibodies (VHH) to potentially improve tumor penetration and facilitate modular construction of multispecific formats. The specific molecular targets within the immune checkpoint pathways have not been publicly disclosed by the developer, but the agent is part of Sysvax's pipeline focusing on next-generation immunotherapy.